enGene Holdings Inc. Common Stock (ENGN) - Total Liabilities
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has total liabilities worth $52.36 Million USD as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ENGN shareholders equity momentum to track the company's year-over-year net asset growth rate.
enGene Holdings Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
enGene Holdings Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhong Yang Technology Co Ltd
TW:6668
|
Taiwan | NT$1.52 Billion |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
USA | $8.85 Million |
|
Torimbia Socimi S.A.
MC:YTRM
|
Spain | €89.87 Million |
|
Nelly Group AB
ST:NELLY
|
Sweden | Skr547.40 Million |
|
Dongsung Corporation
KO:102260
|
Korea | ₩501.16 Billion |
|
Eastern Water Resources Development and Management Public Company Limited
F:7ES1
|
Germany | €16.24 Billion |
|
Calida Holding AG
SW:CALN
|
Switzerland | CHF77.21 Million |
|
Value Valves Co Ltd
TWO:4580
|
Taiwan | NT$1.03 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down enGene Holdings Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ENGN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how enGene Holdings Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of enGene Holdings Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $53.76 Million | +39.41% |
| 2024-10-31 | $38.56 Million | +166.43% |
| 2023-10-31 | $14.47 Million | +213.20% |
| 2022-10-31 | $4.62 Million | +13.96% |
| 2021-10-31 | $4.05 Million | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more